Medicines & Healthcare Products Regulatory Agency (MHRA) Admission – From Watchdog to Enabling Body

Many of us who have been watching events closely during the “Covid-19 pandemic” have been shocked by the speed and ease with which an experimental injection has been rolled out and administered to so many people globally.  Particularly the novel mRNA technology used by Pfizer/Moderna.

This is an experimental gene therapy – openly admitted at the World Health Summit by Stefan Oelrich, member of the Board of Management at Bayer AG and head of the Pharmaceuticals Division in Berlin – I wrote about this on 2nd April… Here

Oelrich stated:-

“If we had surveyed the public 2 years ago – “Would you be willing to take a gene or cell therapy and inject it into your body, we would probably have had a 95% refusal rate.”

I think this Pandemic has also opened people’s eyes [to innovation in a way that was maybe not possible before.”]……

Opening people’s eyes to innovation is one thing but how did this rushed to market experimental product get from lab to needle in such record time.  I believe the statements made recently in an NHS board meeting may go some way to explaining this dangerous phenomena.

NHS England and NHS Improvement Board Meeting in Common – 24th March 2022

June Raine is the current Chief Executive of the Medicines and Healthcare Products Regulatory Agency in the UK.  Raine made a statement during a recent NHS Board meeting which I believe ties in with Oelrich’s statement above about [innovation that was not possible before]….  

https://www.youtube.com/watch?v=8Dr6ri5plwA

She states: –

“As the UK’s Independent Regulator the MHRA is wholly committed to supporting the success of the Life Science’s vision in the NHS and to realising the full potential of this amazing vision.  As an [enabling regulator, no longer a watchdog] and I will highlight briefly 3 main ways:-

First, in terms of [accelerating access to innovative products] via our end to end integrated pathway the Innovative Licensing and Access Pathway which is [attracting huge interest] and is already delivering via the target development profiles that we are co-honing with NICE and our partner organisations.

Secondly, and importantly safety our first priority will be enhanced using real world evidence, new tools methodologies and importantly [putting patients and their perspectives] at the very centre, and;

Thirdly, in supporting the ongoing evolutionary clinical trials regulatory framework which we are about to enhance to take full advantage of our [new freedoms] and to do so for medicines and clinical devices, we are determined to operate in partnership with the NHS as a learning organisation and to be a full partnership partnered in everything that the NHS aspires to do.”

Analysis

Can a “regulator” be an “enabler – is that not a contradicton in terms? [Regulatory Capture?]

One thing I have come to realise, more so whilst covering the “pandemic”, is that you have to pay very close attention to wording.  

You will notice that I have highlighted certain words used throughout Ms Raine’s presentation which I will illustrate and add my personal commentary.  

  • As an enabling regulator, no longer a watchdog – please read the Cambridge Dictionary definitions of these words very carefully.

  • New Freedoms/Accelerating Access to innovative products = [Freedom to Experiment at speed/remove regulatory barriers?]. 

We know that the MHRA “enabled” an experimental innovative product to be unleashed upon the public whilst still in phase 3 of clinical trials – without any medium/long term safety data.

  • Attracting huge interest – Pharmaceutical Industry/Patent holders?].

Statement made in 2015 by Peter Daszak (Head of Eco Health Alliance):-  

“We need to increase public understanding of the need for medical counter measures such as a pan-coronavirus vaccine.  A key driver is the media and the economics will follow the hype.  We need to use that hype to our advantage to get to the real issues.

Investors will respond if they see profit at the end of the process”

  • Putting patients and their perspectives at the very centre [perspectives a very interesting turn of phrase isn’t it]?

“Public Perception” has been the key driver for compliance during the covid era as so eloquently outlined by the Head of Bayer and as the table above demonstrates perception can be affected by perspective.

The manipulation of perception has worked spectacularly well for the medical industrial complex thus far – given their “new found freedoms” why would they stop now?.

Chilling isn’t it?

https://www.youtube.com/watch?v=8Dr6ri5plwA

https://thegreatdeception.is/top-stories/corona-investigative-committee-dr-david-martin-07-09-21/

https://www.ukcolumn.org/ukcolumn-news/uk-column-news-30th-march-2022

https://pediaa.com/difference-between-perception-and-perspective/

https://www.gov.uk/guidance/innovative-licensing-and-access-pathway

https://unitynewsnetwork.co.uk/a-chilling-warning-from-the-past-the-t4-program/

https://yellowcard.ukcolumn.org/yellow-card-reports

https://unitynewsnetwork.co.uk/mhra-contract-for-artificial-intelligence/

 

Leave a Reply

-->
>